TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06318364

Intervention type: OTHER
Intervention: NO Intervention
Description: NO Intervention
Study: NCT05000671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 injection or Placebo(rate=87.5 mg/hr)
Description: To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Study: NCT05042661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture-like transcutaneous electrical nerve stimulation
Description: The intervention group performed Al-TENS therapy 3 times a week for at least 20 minutes each time for 4 consecutive weeks. The second, fourth, and eighth week after the intervention.
Study: NCT05244070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986403
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT04938661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-Based Cardiac Rehab
Description: 36 center-Based Cardiac Rehab Sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-Based Cardiac Rehab
Description: 36 center-Based Cardiac Rehab Sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: Mobile Health Platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: Mobile Health Platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Cardiac Rehab
Description: Encouraged to exercise 3 times per week at home
Study: NCT06110923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-846
Description: once administration of Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-846
Description: once administration of Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-846
Description: once administration of Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-846
Description: once administration of Investigational Product
Study: NCT04468087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
Study: NCT06110923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D091
Description: once administration of Investigational Product per day
Study: NCT04885686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomethasone N RCS
Description: Root canal sealer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endomethasone SP RCS
Description: Root canal sealer
Study: NCT06374485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU409 capsules
Description: Oral administration
Study: NCT04468087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofusbuvir + Daclastavir 60 mg
Description: 400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atazanavir
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sofusbuvir + Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sofusbuvir + Daclatasvir 60 mg
Description: 2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
Study: NCT06046274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous (IV) infusion
Study: NCT05723822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system.
Study: NCT06046274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab IV infusion
Study: NCT05328401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Description: Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
Study: NCT06535139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief training
Description: Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief training
Description: Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief training
Description: Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-targeted motivational aids
Description: Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-targeted motivational aids
Description: Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare access
Description: Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
Study: NCT04087538

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin T and I
Description: Does the use of troponin T or I increase the number of patients referred to coronary angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin T and I
Description: Does the use of troponin T or I increase the number of patients referred to coronary angiography
Study: NCT05606120

Intervention type: DEVICE
Intervention: CL TRAUMA femoral stem
Description: Hip arthroplasty according to the instruction for use.
Study: NCT06112756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT04383496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
Study: NCT06646978

Intervention type: DRUG
Intervention: Imatinib (STI571)
Description: Imatinib-based regimen
Study: NCT05553353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation--Active
Description: Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation--Sham
Description: Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
Study: NCT06247761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure at end of hand surgery
Description: skin closure with vicryl rapide suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure at end of hand surgery
Description: skin closure with vicryl rapide suture
Study: NCT06585683

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation at Day 4
Description: Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
Study: NCT04989790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PICU Up!
Description: PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
Study: NCT05071937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
Study: NCT06390241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin-biotin-Dota-90Y
Description: Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
Study: NCT05229692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUBIE
Description: Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques
Study: NCT06427772

Intervention type: PROCEDURE
Intervention: bipolar hemiarthroplasty
Description: bipolar hemiarthroplasty for neck femur fracture

Intervention type: PROCEDURE
Intervention: bipolar hemiarthroplasty
Description: bipolar hemiarthroplasty for neck femur fracture
Study: NCT05894876

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is provided to the participants as part of this study.

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is provided to the participants as part of this study.
Study: NCT06558994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Description: Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
Study: NCT06558994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Description: Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
Study: NCT05952804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Infusion (Human), 10% Solution
Description: Given IV
Study: NCT06585683

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Evaluation at Day 4
Description: Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Evaluation at Day 4
Description: Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation at week 26
Description: Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Evaluation at week 26
Description: Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
Study: NCT05952804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T Cells Preparation
Description: Given CAR-T treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-CD19 CAR T Cells Preparation
Description: Given CAR-T treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT03759405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPS differentiated cardiomyocytes
Description: Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
Study: NCT06147102

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical treatment for the unruptured intracranial aneurysm

Intervention type: PROCEDURE
Intervention: Endovascular
Description: Endovascular treatment for the unruptured intracranial aneurysm
Study: NCT06585280

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06584864

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bedside ultrasound examination of the lumbar spinal canal
Description: The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
Study: NCT05765409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIMCA
Description: TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes.
Study: NCT06456788

Intervention type: BIOLOGICAL
Intervention: MMR vaccination
Description: MMR vaccination status
Study: NCT05737524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (VAST 2)
Description: The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
Study: NCT06140017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Msingi Bora responsive parenting and family wellbeing program
Description: Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Msingi Bora responsive parenting and family wellbeing program
Description: Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.
Study: NCT05537584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Subjects will receive 8 weeks of sertraline while monitored by the study physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Subjects will receive 8 weeks of sertraline while monitored by the study physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Subjects will receive 8 weeks of bupropion while monitored by the study physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Subjects will receive 8 weeks of bupropion while monitored by the study physician
Study: NCT06194110

Intervention type: DIAGNOSTIC_TEST
Intervention: Ergometric test
Description: Ramp test followed by a step test, both with ergospirometry
Study: NCT06642324

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
Description: Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
Description: Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
Description: Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
Study: NCT06532630

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR-T cells
Description: Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.